FLUCATE MODECATE MOTIVAL MODRIN FLUPHEN FENARAX FENARAX FLUPHAN MOTISONE GENCATE M-KATE FLUFIWAN SYNOCATE PSYCATE SYCATE FLITZIN SAVIGET

Dose: 12.5 to 25 mg
Single Dose: 19 (18.75)
Frequency: As recommended.
Route: IM
Instructions: Initial

Dose:
Single Dose:
Frequency:
Route:
Instructions: Not recommended in this age group

Dose:
Single Dose:
Frequency:
Route:
Instructions: Not recommended in this age group

Fluphenazine decanoate is the derivative of Fluphenazine. It is of Synthetic origin and belongs to Phenothiazine. It belongs to D2 antagonist pharmacological group on the basis of mechanism of action and also classified in Psychotherapeutic Drugs and Antipsychotic Agent pharmacological group.The Molecular Weight of Fluphenazine is 437.50. Its pKa is 3.9.

Fluphenazine is contraindicated in conditions like Blood dyscrasias,Hepatic disease,Coma,Brain damage.

The severe or irreversible adverse effects of Fluphenazine, which give rise to further complications include Tardive dyskinesia, Neurological disturbances.Fluphenazine produces potentially life-threatening effects which include Blood dyscrasias, Malignant neuroplastic syndrome. which are responsible for the discontinuation of Fluphenazine therapy.The signs and symptoms that are produced after the acute overdosage of Fluphenazine include Hypotension, Tachycardia, Hypothermia, Tachypnea.The symptomatic adverse reactions produced by Fluphenazine are more or less tolerable and if they become severe, they can be treated symptomatically, these include Allergic reactions, Skin pigmentation, Galactorrhea, HyperprolactinemiaX, Cholestatic Jaundice, Adverse behavioral reactions, Adverse neurological symptoms, ANS adverse effects, Deposits in lense & cornea.

Fluphenazine is primarily indicated in conditions like Diagnostic procedures, Hypothyroidism, Mania, Muscle spasm of varied aeitology, Post-operative nausea and vomiting, Psychosis, Relief of discomfort in mild UTIs.

Fluphenazine is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAlcoholAtomoxetine HClThe effect and toxicity of atomoxetine could be increased by CYP2D6 inhibitor.Clonidine (HCl)DiazoxideEnhanced hypotensive effect when Diazoxide given with Fluphenazine.Dopamine (HCl)GuanethidineLithiumMethyldopaMetoclopramide (HCl)OxymorphoneCentral nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.ModerateDuring concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Ambulatory patients should be made aware of the possibility of additive CNS effects (e.g., drowsiness, dizziness, lightheadedness, confusion) and counseled to avoid activities requiring mental alertness until they know how these agents affect them. Patients should also be advised to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.Potassium ClorazepateEffects of Potassium Clorazepate may be potentiated by Fluphenazine.PramipexoleFluphenazine may decrease the efficiency of pramipexole due to dopamine antagonism. These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Drug should not be given to Paediatrics, Pregnant Mothers, Geriatrics, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Inj Store Below 40°C. Do not Freeze. Protect from Sunlight and Moisture.

Fluphenazine should be used with caution in patients exposed to extreme heat or phosphorus insecticides, patients in state of alcohol withdrawal, patients with history of peptic ulcer, allergic reactions, with renal (kidney) impairment, prostatic hypertrophy. Photosensitization may occur, caution patients to take appropriate measures i.e. sunscreen e.t.c. against exposure to sunlight or UV light. Discontinue use atleast 48 hrs.before myelography.